Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/30169
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKOC, Ozgur-
dc.contributor.authorDe Smedt, Philippe-
dc.contributor.authorROBAEYS, Geert-
dc.contributor.authorVan Damme, Pierre-
dc.contributor.authorAlmeida, Jorge-
dc.contributor.authorFalkenberg, Frank-
dc.contributor.authorSavekoul, Paul H.M.-
dc.contributor.authorLashof, Astrid-
dc.date.accessioned2019-12-17T12:49:00Z-
dc.date.available2019-12-17T12:49:00Z-
dc.date.issued2019-
dc.identifier.citationJOURNAL OF HEPATOLOGY, 70, p. E149-E149-
dc.identifier.urihttp://hdl.handle.net/1942/30169-
dc.language.isoen-
dc.publisherELSEVIER SCIENCE BV-
dc.subject.otherGastroenterology & Hepatology-
dc.titlePhase II trial to evaluate immunogenicity and safety of a new adjuvanted HBAI20 Hepatitis B vaccine in non-responders: BE RESPONDER-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateAPR 10-14, 2019-
local.bibliographicCitation.conferencenameInternational Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL)-
local.bibliographicCitation.conferenceplaceVienna, AUSTRIA-
dc.identifier.epageE149-
dc.identifier.issue1-
dc.identifier.spageE149-
dc.identifier.volume70-
local.format.pages1-
local.bibliographicCitation.jcatM-
dc.description.notes[Koc, Ozgur; Savelkoul, Paul H. M.; Lashof, Astrid Oude] Maastricht UMC, Maastricht, Netherlands. [Koc, Ozgur; Robaeys, Geert] Ziekenhuis Oost Limburg, Genk, Belgium. [Koc, Ozgur; Robaeys, Geert] Hasselt Univ, Hasselt, Belgium. [de Smedt, Philippe; Van Damme, Pierre] Antwerp Univ, Antwerp, Belgium. [Robaeys, Geert] Katholieke Univ Leuven, Leuven, Belgium. [Almeida, Jorge; Falkenberg, Frank] CyTuVax BV, Maastricht, Netherlands. [Falkenberg, Frank] CIRES GmbH, Bochum, Germany. [Savelkoul, Paul H. M.] Univ Amsterdam, Med Ctr, VUmc, Amsterdam, Netherlands.-
local.publisher.placeAMSTERDAM-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.identifier.doi10.1016/S0618-8278(19)30262-2-
dc.identifier.isi000463481700263-
item.fulltextWith Fulltext-
item.fullcitationKOC, Ozgur; De Smedt, Philippe; ROBAEYS, Geert; Van Damme, Pierre; Almeida, Jorge; Falkenberg, Frank; Savekoul, Paul H.M. & Lashof, Astrid (2019) Phase II trial to evaluate immunogenicity and safety of a new adjuvanted HBAI20 Hepatitis B vaccine in non-responders: BE RESPONDER. In: JOURNAL OF HEPATOLOGY, 70, p. E149-E149.-
item.accessRightsRestricted Access-
item.contributorKOC, Ozgur-
item.contributorDe Smedt, Philippe-
item.contributorROBAEYS, Geert-
item.contributorVan Damme, Pierre-
item.contributorAlmeida, Jorge-
item.contributorFalkenberg, Frank-
item.contributorSavekoul, Paul H.M.-
item.contributorLashof, Astrid-
crisitem.journal.issn0168-8278-
crisitem.journal.eissn1600-0641-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
koc 1.pdf
  Restricted Access		Published version57.54 kBAdobe PDFView/Open    Request a copy
Show simple item record

Page view(s)

64
checked on Jun 22, 2022

Download(s)

2
checked on Jun 22, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.